Pharma wants partners not just data suppliers

Form true partnerships with your clients, keep them happy and make your recommendations short and sweet—that's the message from pharma companies to their marketing research suppliers and consultants, according to a new study by marketRx, a Cognizant Company.

Companies felt that the most important attribute they wanted to see in suppliers was their ability to be a partner, rather than simply providing data. Having a positive relationship with them also scored highly, as did suppliers' ability to provide companies with concise summaries of conclusions and recommendations.

However, while most companies generally viewed their experiences with suppliers as positive, they felt that most have considerable room to improve on working with them as partners and on providing concise summaries. Interestingly, companies reported that they were less concerned about their suppliers offering proprietary techniques and providing normative data.

MarketRx presented the results—considered “directional” only—at the Pharmaceutical Marketing Research Group (PMRG) Annual National Conference in Phoenix last month.

The survey also found that the “preferred provider” model is currently dominant (used by 54% of companies) and will be used increasingly in the next five years at the expense of the “no restrictions on suppliers” model.

The “preferred provider” model scored high on “knowledge of therapeutic area” and “cost to the client,” while the “no restrictions” model came out top on “quality.” 
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.